BioCryst Pharmaceuticals (BCRX) to Release Earnings on Monday

Key Points

• BioCryst Pharmaceuticals (BCRX) will announce its Q2 2025 earnings on August 4th, with analysts predicting earnings of $0.02 per share and revenue of $149.59 million.
• The stock has a current price of $8.55 and a market capitalization of $1.79 billion, with a consensus target price of $16.70 from analysts.
• Recent institutional trading saw significant investments, with Goldman Sachs increasing its stake by 49.6%, now owning 1.93 million shares valued at approximately $14.49 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 4th. Analysts expect BioCryst Pharmaceuticals to post earnings of $0.02 per share and revenue of $149.59 million for the quarter.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock traded down $0.17 on Thursday, reaching $8.06. 2,647,045 shares of the stock were exchanged, compared to its average volume of 3,833,187. The firm's 50 day moving average is $9.68 and its 200-day moving average is $8.71. BioCryst Pharmaceuticals has a one year low of $6.01 and a one year high of $11.31. The firm has a market cap of $1.69 billion, a PE ratio of -30.98, a P/E/G ratio of 1.32 and a beta of 1.04.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Caxton Associates LLP bought a new position in BioCryst Pharmaceuticals in the first quarter worth about $314,000. Royal Bank of Canada boosted its holdings in BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company's stock worth $476,000 after purchasing an additional 1,458 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in BioCryst Pharmaceuticals by 6.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company's stock worth $1,019,000 after purchasing an additional 8,517 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in BioCryst Pharmaceuticals by 11.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company's stock worth $3,363,000 after purchasing an additional 47,355 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in BioCryst Pharmaceuticals by 49.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company's stock worth $14,490,000 after purchasing an additional 640,704 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

Analyst Ratings Changes

BCRX has been the subject of several recent analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $17.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, June 25th. Cantor Fitzgerald initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They set an "overweight" rating and a $20.00 target price on the stock. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 26th. JPMorgan Chase & Co. raised their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $16.70.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.